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ABSTRACT
The current standard treatment of prostate cancer by androgen deprivation therapy
involves using drugs such as bicalutamide (Casodex) to antagonistically block androgen
receptors that are normally present within prostate cells. Usually, the therapy is successful in the
short run at limiting the growth of prostate cancer. However, in virtually all cases tumors begin
to grow aggressively again after several months of treatment and new therapies must be started.
The mechanism by which these prostate cells transform from androgen sensitive to androgen
independent and anti-androgen resistant is unclear. In this study, we investigated the role of
microRNAs, small 15 to 18 nucleotide regulatory RNAs, in regulating the desensitization of
prostate cancer cells to the androgen receptor antagonist drug bicalutamide.
In order to identify significant microRNAs, quantitative PCR was used to obtain genomewide microRNA expression levels of 885 human microRNAs at different timepoints for
androgen sensitive LNCaP cancer cells treated with bicalutamide and for untreated control cells
in tissue culture. Analysis of microRNA expression by clustering analysis and by statistical
comparisons of treatment groups resulted in identification of 28 microRNAs that have altered
expression in the progression process. In silico target prediction analysis was performed with the
microRNAs shown to have altered expression, and a group of genes predicted to be under
microRNA regulatory control during cancer progression to resistance was identified. A
microRNA expression profile can be useful in developing more effective prognostic and
therapeutic tools for prostate cancer.
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INTRODUCTION
Prostate cancer in men represents one of the most persistent challenges to modern
medicine both in terms of its widespread rate of occurrence and in its evasiveness to treatment.
The statistics for prostate cancer are astonishing; according to American Cancer Society
estimates, 1 in 6 men will be diagnosed with prostate cancer in their lifetime and 1 in 36 will die
from it. The Center for Disease Control and Prevention reports prostate cancer as the most
diagnosed cancer in men for all races including populations of Hispanic origin with a combined
incidence rate of 156.9 in 100,000. All fields of cancer research, and especially those dealing
with prostate cancer, require our continued dedication in advancing our understanding of the
mechanisms of carcinogenesis and progression as well as the optimal clinical treatments.

1

BACKGROUND
Clinical Treatment of Prostate Tumors
The majority of patients who present with well localized prostate carcinoma undergo
radical prostatectomy, radiation therapy, or active surveillance. When prostate cancer is not well
localized, standard therapy for patients with more metastatic but androgen-sensitive disease
states is the administration of a combination of drugs used to simultaneously block androgen
receptor function in prostate tissue as well as deplete the levels of androgen produced by the
testes. The therapeutic basis of this tactic is that prostate cancer tissue requires stimulation by
androgen in order to continue to survive and proliferate. Androgen depletion can be achieved by
orchiectomy or by using a gonadotropin-releasing hormone (GnRH) analogue that decreases the
production of luteinizing hormone in the pituitary by strongly binding the GnRH receptor and
causing its down-regulation. At the same time, non-steroidal anti-androgen drugs such as
flutamide (Eulexin), nilutamide (Nilandron, Anandron), or bicalutamide (Casodex) are used to
antagonistically block prostate androgen receptors (Sharifi et al., 2010). From this point on the
disease course is fairly predictable. First, there is a noted decline in serum prostate specific
antigen (PSA) level and a regression of the tumor. After a period of time, usually 18 to 24
months, PSA levels begin to rise, tumor progression returns, and prostate cancer symptoms
become more pronounced (Chen et al., 2009). This stage of prostate cancer is characterized by
resistance to the anti-androgen and androgen deprivation therapy as well as more aggressive

2

metastatic phenotypes. Patients with metastatic androgen independent prostate cancer must seek
stronger chemotherapies such as Docetaxel and Estramustine (Petrylak et al., 2004).
It should be noted that the clinical use of anti-androgen drugs for the treatment of prostate
cancer has potential widespread detrimental effects on the body. Some of the long-term effects of
androgen deprivation therapy include fatigue, loss of bone density, decreased libido and sexual
function, and increases in the rates of diabetes and cardiovascular disease (Alibhai et al., 2006).
Decrease in a patient’s quality of life could also come as a result of a decrease in cognitive
function, though this relationship is not well established (Alibhai et al., 2010; Tadros and
Garzotto, 2011). Nevertheless, it is apparent that the long-term side effects of androgen
deprivation therapy and the certain progression to drug resistance warrants improved clinical
screening techniques for patient-specific drug effectiveness as well as investigation into new
therapies.

Androgen Receptor
The primary ligands for normally functioning androgen receptor are the lipophilic steroid
hormone testosterone and the testosterone derivative dihydrotestosterone (the product of 5αreductase). Androgen signaling is crucial for regulating the development and differentiation of
the male reproductive organs, including the prostate, as well as the secondary sex tissues.
Androgen and its receptor continue to mediate the normal maintenance and function of these
tissues throughout life. Androgen receptor itself is present in the cytoplasm of prostate (and
other) tissues in its inactive form as a 110 kDa class I steroid receptor protein bound to various
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stabilizing proteins such as hsp90, hsp70, and hsp56 (Roy et al., 2001). Lipophilic steroid
androgens are able to diffuse across the lipid bilayer of the cytoplasmic membrane, and upon
binding to the ligand-binding domain of the androgen receptor, cause a conformational change
that leads to dissociation of heat-shock proteins, phosphorylation by kinases, translocation to the
nucleus, and dimerization (Mangelsdorf et al., 1995).
In the nucleus, androgen receptor binds to specific sequences in the genomic DNA
referred to as androgen response elements (AREs). Transcriptional co-activators are recruited to
induce transcription of genes under androgen receptor control, like PSA (Riegman et al., 1991).
PSA is commonly used in research labs and clinics as a reporter of androgen receptor activity,
with high serum levels of PSA suggestive of prostate cancer. In prostate tumors the expression of
androgen-regulated genes leads to cell survival and proliferation. For example, a recent study
showed that the expression of TM4SF1 is under androgen control and that TM4SF1
overexpression increases prostate cancer cell migration (Allioli et al., 2011). There are also some
lines of evidence that suggest androgen receptor has additional roles in activating growth factor
pathways by direct protein-protein interaction, such as through interaction of androgen receptor
and the transcription factor AP-1 (Fronsdal et al., 1998). Androgen receptor pathways are
involved in many cellular processes, but it is clear that the main result of androgen receptor
signaling in prostate cancer is the survival of cancerous prostate cells.
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Androgen Independence
The earliest work on the effects of hormones on prostate cancer was performed by
Huggins and Hodges when they did their Nobel Prize winning work on androgen dependence of
prostate carcinoma in humans and suggested androgen ablation (depletion of circulating
androgen levels) as a treatment for prostate cancer (Huggins, 1957). Several studies have shown
that steroidal anti-androgen drugs, like cyproterone acetate, and non-steroidal anti-androgen
drugs repress growth of prostate cancer cells in vitro (Bologna et al., 1995; Kokontis et al.,
1998). However, clinical use of these drugs leads to castration resistant relapse in virtually all
cases. Several studies have successfully established androgen independent cell-lines by
prolonged passage in hormone-depleted media. Androgen dependent LNCaP-104S cells begin to
die in androgen-depleted media and show a biphasic response to androgen, with low androgen
levels inducing growth and high androgen levels repressing growth but inducing greater PSA
production (Kokontis et al., 1994; Lee et al., 1995). On the other hand, androgen independent
LNCaP-104R cells exhibit unrepressed growth in androgen-depleted media. Interestingly, the
growth of LNCaP-104R cells is repressed by treatment with androgen levels that normally
induce proliferation of LNCaP-104S cells (Kokontis et al., 1998).
The molecular mechanisms of progression from androgen sensitive to androgen
independent during treatment with androgen receptor antagonist drugs like Casodex remains
largely unknown. Several studies over the years have shown that androgen-independent prostate
cells exhibit increased androgen receptor expression and activity (Culig et al., 1999; Kokontis et
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al., 1998). This increase in androgen receptor activity suggests a functional role for androgen
receptor in the maintenance of proliferation in androgen independent cancer. There are basically
three theories proposed for the role of androgen receptor in the acquisition of androgen
independence: activation of androgen receptor by secondary ligand, ligand independent
activation of androgen receptor, or activation of an androgen receptor bypass mechanism.
Some evidence points towards the possibility that the androgen receptor becomes
activated by certain non-steroidal growth factors and cytokines like IGF-1, KGF, EGF, and IL-6
in the androgen independent state (Jenster, 2000). One study showed that a point mutation in
androgen receptor changes the effects of cyproterone acetate and the non-steroidal anti-androgen
hydroxyflutamide so that the receptor is capable of recruiting the same co-regulators as if it were
activated by androgen, essentially conferring agonist properties on the anti-androgen molecules
(Berrevoets et al., 2002). Studies have also identified androgen receptor mutations that greatly
increase the affinity of the androgen receptor steroid binding domain to very low androgen
concentrations (Thin et al., 2003). The increased affinity to androgen may mean that the
extremely low amount of androgen produced during implementation of an androgen deprivation
strategy can preferentially bind the receptor. Additionally, strong amplification of the androgen
receptor seen in some androgen independent prostate tumor samples, as well as the LNCaP-104R
cell line, could increase the ability of the receptor to be activated by secondary ligand, possibly at
a site separate from the androgen-binding domain (Ford et al., 2003).
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On the other hand, it may be that a ligand is not required for activation. It has been shown
that the androgen receptor is capable of ligand-independent interaction with the transcriptional
coactivator SRC1 in the nucleus, causing transcription at certain promoters in the absence of
androgen (Powell et al., 2004). It has also been proposed that an androgen receptor bypass
mechanism might be important to progression, mediated through cytokines or other survival
factors. One recent microarray investigation found that the proteins TWIST1, VAV3, and DKK3
could be important to a bypass pathway, resulting in downstream expression of survival factors
(Marques et al., 2010).

MicroRNA
The apparent elusiveness of a direct mechanism for the regulation of prostate cell
progression to CDX-resistance has led many to suggest that a more complex regulatory network
is at play. In fact, the progression mechanisms of many cancer types appear to be mediated by
complex regulatory processes consisting of protein and RNA elements. Recent evidence suggests
that the progression of multiple human cancers, including prostate cancer, is mediated by a
growing class of small non-coding RNAs called microRNAs (miRNA). These short, ~22
nucleotide-long, single-stranded RNAs regulate human genes by binding to imperfectly
complementary sequences on the 3’ un-translated region (3’ UTR) of target mRNA transcripts.
Binding of the miRNA and its associated silencing complex to the mRNA transcript inhibits
translational elongation, thus leading to post-transcriptional negative gene regulation (see Mode
of Regulation). In some instances there is potential for great complexity in gene regulation by
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miRNAs, as studies have shown that a single miRNA may target up to 200 different genes and
that a single gene can be regulated by many miRNAs (Lim et al., 2005). The first miRNA
identified, lin-4, was found to be implicated in the larval development of C. elegans (Lee et al.,
1993). Lin-4 was also the first miRNA to have its regulatory function characterized when it was
discovered that lin-4 targets the mRNA transcript of the protein-coding gene lin-14 and
temporally mediates transition between larval stages L1 and L2 (Wightman et al., 1993). Since
then, several hundred human miRNAs have been identified and implicated in a diverse array of
cellular processes including differentiation, cell proliferation, apoptosis, stress response,
immunity, transcription, and tumorigenesis.
Biogenesis
Genes encoding miRNAs are found throughout the human genome with a large number
of miRNA genes believed to be transcribed as polycistronic units utilizing their own promoters
(Cai et al., 2004). However, some miRNAs have been found encoded in the intronic regions of
other known genes (Lagos-Quintana et al., 2001). MiRNA genes are transcribed by RNA
Polymerase II into long transcripts of several thousand bases that are then cleaved by the RNase
III enzyme Drosha and its cofactor DGCR8 while in the nucleus. The resulting pri-miRNA is
~70 nucleotides long and forms an imperfect hairpin-loop structure. Active transport of the primiRNA out of the nucleus and into the cytoplasm is mediated by the nuclear membrane proteins
Exportin-5 and RAN-GTP. Once in the cytoplasm the pre-miRNA transcript comes into contact
with the enzyme Dicer and the RNA-binding protein TRBP which cleave the hairpin structure
from the transcript, leaving an imperfectly complementary miRNA/miRNA* duplex consisting
8

of the guide strand mature miRNA sequence and the passenger strand miRNA. The guide strand
of the miRNA/miRNA* duplex is preferentially incorporated into a multi-protein RNA-induced
silencing complex (RISC) referred to as the miRISC, similar to the siRISC involved in RNAi
silencing (Kim, 2005; Lee et al., 2002).
Mode of Regulation
Regulation of translation by miRNAs has been seen across eukaryotic and bacterial
domains, and even in archaea. The bulk of miRNA research has focused on eukaryotic gene
regulation, and it appears that differences exist in the modes of miRNAs translational repression
between plants and animals. Generally, miRNA gene regulation in plants involves near perfect
sequence complementarity between guide strand miRNA and mRNA target, inducing mRNA
degradation through the RNAi pathway. Additionally the miRISC of plants binds the target
mRNA transcript at sites within the coding region of the mRNA (Hannon, 2002). A conserved
Argonaute protein in the RISC (Ago2 in humans) mediates the RNA-cleaving “slicer” activity of
the complex where perfect miRNA/mRNA base pairing occurs. The only mammalian miRNA
known to lead to mRNA cleavage is miR-196 when it binds to Hoxb8 mRNA (Yekta et al.,
2004). Human miRNAs generally do not exhibit perfect sequence complementarity and do not
induce mRNA degradation. As part of the miRISC, the guide strand sequence targets binding of
the miRNA to semi-complementary sites on the 3’ UTR of target mRNA sequences. The
translation of these target genes is repressed due to the association of miRISC with the transcript
(Esquela-Kerscher and Slack, 2006; Pillai et al., 2005). Two models have been proposed for
miRNA-induced translational repression, and both involve processing bodies (PBs) in the
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cytoplasm. PBs are known to mediate normal mRNA degradation and turnover. In the first
model, the miRISC bound at the mRNA 3’ UTR interacts with the 5’ m7Gppp cap. This
interaction interferes with recruitment of the E1F4E translation factor that is responsible for
directing the transcript to the ribosome. Translationally repressed mRNAs are then directed to
PBs for degradation or possibly storage. In the second model initiation is not affected, but
binding of the miRISC to the 3’ UTR directs the mRNA to PBs where translation cannot occur
(Pillai, 2005).

Roles for MicroRNAs in Cancer
The relatively recent emergence of high-throughput miRNA expression profiling
techniques has begun to shed light on the various roles that miRNAs play in cancer. Microarray
studies have shown that aberrant miRNA expression is correlated with several human cancers
and that many miRNAs can be classified as oncogenes or tumor suppressor genes. The first
miRNAs to have their expression associated with human cancer were miR-15a and miR-16-1.
They have been shown to target the tumor-suppressor survival gene Bcl-2 and to be downregulated in B-cell chronic lymphocytic leukemia (Cimmino et al., 2005). Other examples of
cancer-related miRNAs are miR-143 and miR-145, which are down-regulated in many cancer
cell-lines (breast, prostate, cervical, and lymphoid cancer) as well as in colorectal tumors (Iorio
et al., 2005; Michael et al., 2003). The conserved expression pattern across multiple cancer types
indicates a generalized tumor suppression function of these miRNAs. The miRNA oncogene
miR-21 has been found to be greatly overexpressed in glioblastoma tumors where it inhibits
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apoptosis (Chan et al., 2005; Ciafre et al., 2005). Up-regulation of miR-21 expression has also
been shown in breast cancer and prostate cancer where this miRNA may potentially have an
oncogenic function (Iorio et al., 2005). The first class of miRNAs shown to regulate an oncogene
was the let-7 miRNA family, which mediates expression of the Ras oncogene (Johnson et al.,
2005). It has been found that among lung cancer patients let-7 miRNA is most down-regulated in
those that exhibit poor post-operative survival and overall poor prognosis. Additionally,
expression of let-7 in lung cancer tissue has been shown to inhibit proliferation (Takamizawa et
al., 2004).

MicroRNA Regulation in Prostate Cancer
With the overwhelming evidence that miRNAs have roles in various cancers, it is not
surprising that there are recent indications that several miRNAs are implicated in the
tumorigenesis and progression of prostate cancer (Catto et al., 2011). MiR-221 and miR-222
have been shown to be up-regulated in androgen independent prostate cancer cell lines and to
target the p27/kip1 tumor suppressor gene (Sun et al., 2009). High throughput microarray
analysis of miRNA expression in prostate cancer cell lines shows that miR-21 expression is
induced by androgen-stimulated androgen receptor and, indeed, that miR-21 alone is sufficient
for maintaining a castration-resistant phenotype in prostate tumors in vivo (Ribas et al., 2009).
Interestingly, it has also been shown that miR-21 targets PDCD4 and PTEN, two known antisurvival genes (Lu et al., 2008; Papagiannakopoulos et al., 2008). MiRNAs of the miR-17-92
family target the degradation of E2F transcription factor mRNA. In fact, it has also been shown
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in prostate cancer cell lines that transcription factors of the E2F family are responsible for
transcription of miR-17-92 family miRNAs. It is believed that a miRNA-mediated regulatory
feedback loop is in place to control E2F expression here.
Androgen-induced AR has also been shown to mediate expression of miR-125b. This
miRNA inhibits translation of Bak1 and induces androgen independent growth in transiently
infected prostate cancer cells (Shi et al., 2007). One study found that miR-146a is downregulated in androgen-independent prostate cancer cells and proposed a possible mechanism of
androgen independence by showing the negative regulation of the ROCK1 oncogene by miR146a (Lin et al., 2008). The miRNA miR-145 is down-regulated in many cancers including
prostate cancer and has been shown to target the BNIP3 gene. Low expression levels of miR-145
and high BNIP3 expression levels in prostate tumors are associated with unfavorable patient
outcomes (Chen et al., 2010). Given the numerous examples of miRNAs implicated in prostate
cancer, it is hypothesized that miRNAs play essential roles in the progression of prostate cancers
to Casodex resistance.
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OBJECTIVE OF THE STUDY
This study aimed to investigate the deregulation of miRNAs in human prostate cancer
and the possible functional roles of deregulated miRNAs in the progression of prostate cancer
cells toward anti-androgen resistance. Several major aspects of the study should be noted. Our
primary focus was the measurement of miRNA levels at timepoints during anti-androgen
treatment so that we could track time dependent miRNA changes that may have regulatory
consequences. Due to the apparently complex nature of the androgen independence mechanism,
a time dependent approach to screening miRNA expression during progression was central to the
experimental design. Another important aspect of the study was the comparison of miRNA
expression levels in anti-androgen treated cells to timepoint-paralleled androgen depleted cells so
that we could isolate miRNAs that are deregulated due to the effects of anti-androgen binding to
androgen receptor (and possibly additional mechanisms) separate from the effects of general
androgen deprivation. Few studies have been so precise in their distinction between the changes
that occur during castration resistance and anti-androgen resistance. The third focus of the study
was to make use of the enormous amount of bioinformatics research that has been carried out to
develop miRNA target prediction techniques. Several labs have created algorithms with the aim
of predicting which mRNA transcripts specific miRNAs target. These algorithms that take
several binding factors into account and the prediction results are made publically available
online. A large portion of this study utilized in silico analysis techniques.
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MATERIALS AND METHODS
Experimental Plan
The experimental plan was comprised of two phases:
•

M1 – Data acquisition, consisting of cell culture and treatment, western blot, and
miRNome screening by qPCR

•

M2 – Data analysis, consisting of statistical analysis of expression data and in
silico target prediction

M1. Cell culture and cell treatment
Principle
The LNCaP cell line is an androgen sensitive prostate cancer cell line widely used in
androgen deprivation experiments. Originally isolated from a lymph node metastasis of a
primary prostate tumor, LNCaP cells express androgen receptor containing a T868 to A868
mutation in the steroid binding domain. This mutation increases the affinity of the receptor
protein for some anti-androgen molecules, including bicalutamide, and allows the signaling
effects of anti-androgens to be more easily studied. (Veldscholte et al., 1992; Veldscholte et al.,
1990). LNCaP-104S and LNCaP-104R1 are the sub-lines used in this study. LNCaP-104S cells
are androgen sensitive and require androgen stimulation for growth. The line was established by
selecting an LNCaP clone that demonstrated maximal proliferation with stimulation by 0.1 nM
of synthetic androgen (Kokontis et al., 1994). The LNCaP-104R1 line was created by prolonged
14

passage in androgen depleted media for several months (80 to 100 passages) and is characterized
as having a moderately aggressive drug resistant phenotype. LNCaP-104R1 cells grow
unrepressed in androgen-depleted media but are repressed by levels of androgen that induce
maximal LNCaP-104S proliferation (Kokontis et al., 1994). LNCaP-104R1 cells were utilized so
that miRNA expression during anti-androgen treatment could be compared to expression in an
established androgen independent line.
Experimental design
Cell culture of androgen sensitive LNCaP-104S cells was maintained before drug
treatment in DMEM/10% FBS and 1 nM DHT with passage at 70% confluency. Culture of
androgen independent LNCaP-104R1 cells was maintained in DMEM/10% FBS with passage at
70% confluency. All treatments of LNCaP-104S cells were initiated by 48 hours of androgen
depletion in DMEM/10% charcoal-stripped FBS (CS-FBS) media. For protein experiments,
LNCaP-104S cells were treated with either 10 nM DHT or 5 µM Casodex (CDX) and harvested
at zero hour, 24 hours, 48 hours, and 72 hours timepoints. For qPCR miRNA screening, LNCaP104S cells were treated with 5 µM Casodex in DMEM/10% CS-FBS media or only DMEM/10%
CSFBS and harvested at one week and three weeks timepoints. LNCaP-104S and LNCaP-104R1
cells were also harvested at zero hour timepoint (before treatment with CDX).
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M1. SDS-PAGE and western blot
Principle
The standard technique for resolving and identifying proteins from extracted cellular
lysates is SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) followed by
transfer to a protein-binding membrane, such as a PVDF (polyvinylidene fluoride) membrane,
and western blot procedure using a primary antibody specific for the protein of interest. SDSPAGE involves denaturing extracted proteins by boiling in the presence of sodium dodecyl
sulfate and with the reducing agent β-mercaptoethanol. Besides general denaturation, βmercaptoethanol reduces any tertiary disulfide linkages. Sodium dodecyl sulfate binds to and
linearizes denatured polypeptides and imparts a uniform negative charge on all peptides. In this
way, all protein subunits can be resolved by electrophoresis based only on size. Electrophoretic
separation is performed in a thin polyacrylamide gel. Small pores in the bis-acrylamide lattice
allow smaller polypeptides to migrate at a faster rate toward the anode when an electric current is
applied. A standard protein ladder is run simultaneously so that the sizes of proteins can later be
ascertained.
Transfer of the separated proteins is achieved by applying an electric current in a
direction such that the negatively charged polypeptides migrate out of the gel and bind to an
adjacent piece of protein-binding membrane. After staining the membrane with India ink to
visualize the sample lanes, blocking with milk proteins ensures that all the protein-binding sites
on the membrane are unavailable. Next, each lane is incubated with an appropriate concentration
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of primary antibody specific for the protein of interest. After several rounds of rinsing to remove
excess antibody and another round of blocking, the blot is incubated with an appropriate
concentration of secondary antibody. The secondary antibody specifically binds to the constant
regions of all immunoglobulins produced by a given species. The secondary antibody that is used
is determined by the source of the primary antibody. The secondary antibody is also conjugated
to a chemical that provides a means of visualization, commonly the enzyme horseradish
peroxidase (HRP) which produces a fluorometric molecule in the presence of its substrate. When
HRP-conjugated secondary is used, the protein of interest can easily be visualized by addition of
the HRP substrate and developing on autoradiography film or with a western blot visualization
system.
Experimental design
LNCaP-104S cells were maintained in CS-FBS for 48 hours and then treated with CDX
or DHT. Cell samples were harvested by trypsinization at the following timepoints: zero hour, 24
hours, 48 hours, and 72 hours. Cells were lysed using the freeze-thaw method with Halt
phosphatase inhibitor. Protein concentration was measured by Bradford assay and proteins were
resolved by SDS-PAGE separation. After transfer to PVDF membrane, western blot for
androgen receptor was performed with mouse monoclonal IgG1 anti-AR primary antibody (U.S.
Biological, Swampscott, MA) (1:2,500 in TBS-T/5% milk) and HRP-conjugated goat polyclonal
IgG anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc, West Grove,
PA) (1:20,000 in TBS-T/5% milk). GAPDH was used for loading control. Western blots were
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visualized by adding West Femto chemiluminescent substrate (ThermoFisher Scientific,
Waltham, MA) to the secondary-probed membrane and then exposing and developing on
autoradiography film.

M1. Reverse transcription
Principle
Due to the requirement of template DNA when carrying out qPCR reactions for cell
expression studies, it is usually necessary to convert the RNA isolated from a sample of cells to
complementary DNA sequences (cDNA) for amplification. The reverse transcriptase enzyme
was discovered in retroviruses that use it to insert viral genetic code into the DNA genomes of
infected cells (Rodgers et al., 1995). In the lab, reverse transcriptase isolated from retroviral
sources is added to RNA samples along with oligo-deoxythymidine primers, which bind to polyadenosine tails of mRNA transcripts. Small RNAs are not expressed with poly-adenosine tails so
this step necessitates first adding poly-adenosine to all RNAs in the sample using a polyadenylate ligase. Once tails have been added and cDNA has been created from the RNA
sequences in the sample, expression screening by qPCR can commence.
Experimental design
Cells were harvested by trypsinization and pellets were lysed with SBI Cells-to-Cts lysis
buffer. SBI DNase I buffer was used to degrade DNA in the lysate. The SBI System Biosciences
QuantiMir Small RNA Quantitation kit was used to tag all small RNAs in the lysate with poly-
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adenylate tails, bind universal oligo-deoxythymidine primers, and convert total RNA to cDNA
with reverse transcriptase.

M1. Quantitative polymerase chain reaction
Principle
The quantitative polymerase chain reaction technique is used to quantify the number of
DNA copies of any specific sequence in a mixture of template DNA. It is a derivative of the
more simple DNA amplification technique called the polymerase chain reaction. The standard
polymerase chain reaction (PCR) is used to amplify the number of copies of a specific DNA
sequence present in a reaction mixture. The required components of a PCR reaction mixture are
as follows: forward and reverse primers for the DNA sequence of interest, DNA polymerase with
a high temperature range (such as Taq polymerase), dNTPS, optimized cationic PCR buffer
(usually containing potassium and magnesium ions), and the template DNA mixture. Using a
thermocycler, the reaction mixture is subjected to successive rounds of temperature changes each
consisting of a DNA denaturation phase of ~95°C, a primer annealing phase of ~60°C, and a
transcript elongation phase of ~72°C. After approximately 30 cycles, the number of copies of a
DNA sequence of interest will be have been amplified by several orders of magnitude. PCR
amplification is extremely useful and has become central to almost all other DNA research
techniques.
Quantitative real time PCR (qPCR) takes advantage of the exponential nature of PCR
amplification and the quantitative aspects of spectrophotometry to quantify the initial amount of
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any specific DNA sequence in a sample of template DNA. One method of doing this is to add
SYBR green reporter dye to the PCR reaction mixture and then perform the PCR reaction on a
specialized quantitative thermocycler. SYBR green dye binds to double stranded DNA as it is
synthesized in the PCR reaction. Upon binding to double-stranded DNA the emission properties
of SYBR green dye changes so that it emits green light (λ of ~522 nm) when excited by a laser,
allowing the amplification of DNA to be measured in real time. For most data analysis methods,
the qPCR thermocycler measures the green light emission of each well in a reaction plate and
then calculates the exact PCR cycle at which the total green light emission from a well reaches a
predefined threshold value (i.e. the total amount of amplified dsDNA in a well reaches a
predefined value). To be valid, the threshold fluorescence must fall within the exponential phase
of DNA amplification. This cycle number is referred to as the cycle threshold value (Ct). When
used in conjunction with reverse transcription, quantitative polymerase chain reaction is a
powerful method of quantifying RNA expression levels of genes. Isolated RNA from a sample
must first be converted to cDNA by reverse transcriptase, and then qPCR can be used to measure
levels of cDNA.
Experimental design
Genome-wide human miRNAs were screened by reverse transcription to cDNA and then
SYBR green qPCR reaction on an ABI 7900 HT real time thermocycler. MiRNA-specific
primers were provided in the SBI System Biosciences miRNome profiling kit encompassing 885
human miRNAs and three endogenously expressed small RNAs for plate controls (Human U6
snRNA, RNU43 snoRNA, and Hm/Ms/Rt U1 snRNA). Additionally, universal oligo20

deoxyadenosine reverse primers provided in the SBI System Biosciences kit were used in the
qPCR reaction. A Ct value was obtained for each miRNA that amplified without error. All plate
controls were amplified without error.

M2. Delta-delta-Ct analysis
Principle
Several factors are considered during experimental design and multiple strategies have
been developed for analyzing qPCR expression data. For experiments that require the calculation
of an absolute quantity of template DNA, accurate analysis necessitates the creation of a standard
curve using standard reactions of known template quantity and then comparison to the test Ct
value. On the other hand, most expression experiments do not require absolute quantification, but
rather make use of relative expression quantification compared to some control group. If this is
the case, the most common method of data analysis is the delta-delta-Ct method (ΔΔCt method)
(Cikos et al., 2007).
The ΔΔCt method requires no standard curve, is generally easier to perform than the
standard curve method, and involves a simpler calculation than most other analysis methods
(Livak and Schmittgen, 2001). In addition to having to include a control group in the
experimental design, the ΔΔCt method calls for the inclusion of a set of reactions to amplify
endogenously expressed control genes (housekeeping genes) called plate controls to normalize
the expression data for plate-wide variations in amplification efficiency. For most mRNA
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expression studies plate control genes such as GAPDH are used, while in miRNA expression
studies endogenously expressed housekeeping small RNAs are used.
To accurately analyze expression data using the ΔΔCt method, it is helpful to determine
gene-specific average amplification efficiency for each gene being measured. This can be done
several ways, but the gene-specific efficiency is usually calculated by running qPCR reactions of
serially diluted template DNA for each gene, plotting the log concentration vs. Ct, and then
calculating the efficiency as

(Yuan et al., 2008). The ΔΔCt method results in a fold

amplification value that incorporates the test gene expression and the reference gene expression.
If the gene-specific amplification efficiencies of the sample reaction and plate control reaction,
Pc, (test group, T, and reference group, R) are close to equal, the various efficiencies will cancel
out and the equation for fold amplification value can be simplified quite a bit. The formula for
fold amplification value determination with the assumption of equal amplification efficiencies is
part of the Excel software included in the SBI System Biosciences Small RNA Quantitation kit
and is as follows:

The resulting value is a ratio of test expression to reference expression and can be further
analyzed in many ways. It should be noted that as a ratio of expression it is sometimes beneficial
to transform the fold amplification value to the negative reciprocal value for visualization
purposes and some statistical uses. For example, a miRNA that shows half the expression in the
test group as it does in the reference group will have a fold amplification value of 0.5. This value
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can be transformed to its negative reciprocal, -2.0, showing that the miRNA was down-regulated
two-fold.
Experimental design
All Ct values obtained from qPCR screening were analyzed using the ΔΔCt method. For
the initial analysis, the treatment group LNCaP-104S zero hour was designated as the reference
group and compared to all other treatment groups to calculate fold amplification values. In the
initial analysis all fold amplification values deregulated above three-fold (up or down) were
considered to be significant. All ΔΔCt calculations were performed in Microsoft Excel.

M2. Cluster analysis
Principle
Much insight into the gene networks that regulate cellular processes can be offered by
clustering analysis methods that attempt to identify groups of genes with related functions based
on expression data (Gitter et al., 2010). The dynamic and complex nature of miRNA regulation
makes clustering approaches to data analysis very useful. Hierarchical clustering can identify
large-scale expression patterns of groups of miRNAs that have the same regulatory functions,
and offers a way to visualize such groupings. Hierarchical clustering involves calculating
distances between groups of genes (based on expression values) and then determining clustering
solutions by iterative processing of all possible groupings. Two of the main considerations of
clustering analysis are the method of measuring distance or similarity between groups and the
type of hierarchical clustering algorithm that is used. The clustering software Gene Cluster 3.0
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offers several options for determining distance or similarity (correlation, absolute correlation,
Spearman rank correlation, Kendall’s tau, Euclidean distance, and city-block distance ) and for
hierarchical clustering method (centroid linkage, single linkage, complete linkage, and average
linkage)(de Hoon et al., 2004).
Experimental design
Hierarchical clustering was performed on the expression data obtained from the initial
ΔΔCt calculations using the LNCaP-104S zero hour control. Data was clustered using correlation
measurement for similarity and complete linkage. Both the miRNAs and the treatment arrays
were hierarchically clustered and reordered. The analysis was visualized as a heat map and
hierarchical clustering dendrogram with the visualization program Java Treeview (Page, 1996).

M2. Additional comparisons
Principle
After the initial calculations of fold amplification values using LNCaP-104S zero hour as
the control group, the comparison groupings were altered to study specific aspects of progression
to drug resistance. Since the objective of the study involved identifying outliers in the expression
set, it was necessary to calculate the average changes in expression and average deviation from
the mean value. The measure of central tendency most suitable for this type of expression data is
the geometric mean due to the multiplicative nature of the expression values and the decimal
form of all down-regulated expression values. The formula for geometric mean is as follows:
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and once the geometric mean has been calculated the geometric standard deviation can be
calculated as

where Ai denotes an individual fold amplification value. Once the standard deviation has been
determined for each comparison set it is possible to determine z-scores in order to identify the
miRNAs that show expression changes in the significant regions of either tail of the expression
distribution. The standard formula for z-score is

The standard z-score method was used for determining the z-score for all expression values
greater than or equal to 1.0. Z-scores for negatively regulated miRNAs were calculated by
negative reciprocal transformation of the fold amplification value and then addition of 2 before
subtracting the mean value and dividing by the standard deviation:

25

Adding two insures that the distance of the negative reciprocal-transformed fold amplification
value from the mean fold-expression value is accurate, since baseline expression change in our
data was defined as 1.0 (meaning, a value of 1.0 denotes no change in expression). Additionally,
also due to defining 1.0 as the baseline expression change, all geometric mean values determined
to be less than 1.0 were negative reciprocal transformed for use in subsequent calculations. In
order to avoid the assumption that miRNA expression is normally distributed, z-scores were only
used as a means of selecting an arbitrary threshold and not as a means of assigning numerical
significance.
Experimental design
The comparisons used are outlined in Table 1. The comparisons using LNCaP-104S one
week and three weeks CDX treatment timepoints and the respective LNCaP-104S CS-FBS
media treatment timepoints as reference samples show the relative miRNA expression changes
due only to CDX treatment throughout the treatment regimen. The third comparison, relating
LNCaP-104S cells treated with CDX for three weeks to a reference sample of LNCaP-104S cells
treated with CDX for one week, is another way of studying progressive changes in miRNA
expression during a CDX treatment regimen. This comparison better represents miRNA
expression changes in the scenario of CDX treatment of androgen sensitive prostate cancer in
concert with androgen deprivation therapy, since androgen deprivation dependent expression
changes are not being adjusted for. Finally, the comparison of LNCaP-104S cells treated with
CDX for three weeks to LNCaP-104R1 zero hour cells is another way to isolate only CDXdependent changes in miRNA expression. However, differences between this comparison and
26

the CDX versus CS-FBS comparisons are expected due to widespread cellular differences
between the androgen sensitive LNCaP-104S cells and established androgen resistant LNCaP104R1 cells.
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Table 1) Cell lines, treatments, and timepoints for test and reference samples of Comparisons A through D
Test Sample

Reference Sample

Cell Line

Treatment

Timepoint

Cell Line

Treatment

Timepoint

A

LNCaP-104S

CSFBS/5µM CDX

One week

LNCaP-104S

CSFBS

One week

B

LNCaP-104S

CSFBS/5µM CDX

Three weeks

LNCaP-104S

CSFBS

Three week

C

LNCaP-104S

CSFBS/5µM CDX

Three weeks

LNCaP-104S

CSFBS/5µM CDX

One week

D

LNCaP-104S

CSFBS/5µM CDX

Three weeks

LNCaP-104R1

CSFBS

Zero hour
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MiRNAs shown to be up- and down-regulated in the comparisons of Table 1 were
subjected to cross-comparison analysis using Venn diagrams and the Venny tool available online
(http://bioinfogp.cnb.csic.es/tools/venny/index.html). Calculations of standard deviation and zscore were performed by the previously described method. Expression fold-changes greater than
two standard deviations from the mean expression fold-change (z-score less than -2 or greater
than 2) were considered significant at this point in the data analysis.

M2. Target prediction
Principle
In recent years there has been an attempt to develop public databases of miRNA targets
so that researchers may draw conclusions from the huge amount of data becoming available.
Some bioinformatic studies have resulted in the development of algorithm-based methods to
predict the gene targets of known mature miRNA sequences based on several factors. The
miRDB database presents predicted miRNA-target matches and assigns each match a score from
50 to 100, representing the probability that the given mRNA is actually targeted. The target
predictions are calculated using an algorithm designed to take into account seed conservation,
other seed types, base composition, secondary structure, and location on the 3’ UTR. The
developers used a machine learning strategy called Support Vector Machines (SVM) to
systematically search known miRNA target data to optimize the algorithm. The database is
public and can be searched online (http://mirdb.org/miRDB) (Wang, 2008; Wang and El Naqa,
2008). Another publically available database of miRNA target predictions, TargetScan Human
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release 5.1, can be searched as well. TargetScan Human assigns a context score to predicted
targets based on site-type contribution, 3’ pairing contribution, local AU contribution, and
position contribution (http:// targetscan.org/) (Friedman et al., 2009; Grimson et al., 2007; Lewis
et al., 2005).
Experimental design
MiRNAs identified as significantly deregulated were inputs in target scan analysis using
the internet-based target predictions software program miRDB (http://mirdb.org/miRDB). Target
prediction results returned for up-regulated and down-regulated miRNAs were ranked first by the
number of hits from the respective array of candidate miRNAs, and secondly by the arithmetic
average of miRDB scores. Due to the large number of predicted target genes, only targets that
received hits from multiple miRNAs and that received at least one hit with an miRDB score of
80 or greater (for down-regulated miRNAs) or 90 or greater (for up-regulated miRNAs) were
included in the final lists of predicted targets. The target predication program TargetScan Human
(http://targetscan.org) was used for validation of predictions.

30

RESULTS
To verify the expression of androgen receptor and the responsiveness of the LNCaP-104S
cell line to androgen stimulation, western blotting for androgen receptor was performed with
treated samples. Total protein extracted from LNCaP-104S cells treated with DHT and cells
treated with Casodex at timepoints of zero hour, 24 hours, 48 hours, and 72 hours was subjected
to SDS-PAGE and western blot, shown in Figure 1. LNCaP-104S cells treated with Casodex and
treated with DHT did not show significant changes in androgen receptor expression from the
zero hour. Androgen receptor expression in the LNCaP-104S was verified by western blotting.
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Figure 1) Western blot of androgen receptor (110 kDa) in Casodex-treated androgen sensitive LNCaP-104S
cells and in DHT-treated androgen sensitive LNCaP-104S cells at zero hour, 24 hours, 48 hours, and 72 hours
timepoints; GAPDH loading control
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The Ct results of miRNome screening in five LNCaP-104S treatment groups (zero hour,
one week CS-FBS, three weeks CS-FBS, one week CDX, three weeks CDX) and the androgen
independent zero hour LNCaP-104R1 group were processed using the ΔΔCt method with
LNCaP-104S zero hour as the control group for each, and then compiled into a color-coded table
of miRNA expression values, presented as Table 2. The standard rule of thumb that three-fold
changes in expression, positive or negative, are to be considered significant miRNA expression
changes was used as the initial method of looking at patterns across the five columns of ΔΔCt
data. Fold amplification values with green backgrounds are greater than 3.0 and those with red
backgrounds are less than -3.0 (corresponding to a threshold of 0.33 for untransformed fold
amplification values). A value of 0.00 indicates that no cDNA amplification was detected, either
because of extremely low miRNA expression level or an error in amplification.
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Table 2a) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2b) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2c) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2d) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2e) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2f) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold

39

Table 2g) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2h) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2i) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2j) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2k) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold
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Table 2l) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4104S 3 wk CDX, 5- 0 hr 104R; All values are comparisons with 0 hr 104S; Green denotes change > 3 fold;
Red denotes change < -3 fold
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Complete linkage hierarchical clustering analysis was carried out using miRNAs that had
fold amplification data for at least three of the five groups in Table 2. The horizontal order of
miRNAs and the vertical order of treatment groups were arranged into clusters, with more
similar elements ordered closer together in the heat map, presented in Figure 2. Up-regulated
expression appears as red and down-regulated expression appears as green. Hierarchical cluster
dendrograms were constructed for the miRNAs and treatments to visualize how individual
miRNAs and treatments were grouped. It can be seen that distinct clusters of up- and downregulated miRNA genes emerged from the hierarchical clustering exercise. Of the miRNAs
included the in analysis, 199 exhibited general patterns of up-regulation with treatment, and 599
exhibited general patterns of down-regulation. A cluster of 99 miRNAs showed a consistent
pattern of strong up-regulation and a cluster of 241 miRNAs showed a consistent pattern of
strong down-regulation.
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Figure 2) Heat map of clustered miRNA expression across all treatment groups using LNCaP zero hour
expression as reference
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The raw Ct data was then processed by the ΔΔCt method using different treatment groups
as reference groups than had been previously been used in an attempt to better analyze miRNA
changes that occur due to the effects of CDX-treatment. Fold amplification values were
determined according to the comparisons listed in Table1. The miRNAs were ranked according
to fold amplification values for each comparison. Tables 3 and 4 contain the top ranked upregulated and down-regulated results, respectively. The miRNAs that are included in these tables
have fold-amplification values that are at least two standard deviations removed from the mean
change in expression for the comparison (this corresponds to z-scores ≥ 2.0 or ≤ -2.0; refer to
Materials and Methods for a description of the method for determining z-scores). MiRNAs that
have fold amplification values greater than three standard deviations above the mean are denoted
with green backgrounds in Table 3, and those with fold amplification values greater than three
standard deviations below the mean are denoted with red backgrounds in Table 3. The letter
denotation of each comparison can be referenced in Table 1. Assigning significance based on zscore proved to be a more conservative approach than the three-fold method and decreased the
total number of miRNAs considered significant; the category containing the greatest number of
significant miRNAs was the down-regulated portion of comparison D with 56 miRNAs, and the
up-regulated portion of comparison D included only 8 miRNAs. The average fold-changes in
expression for comparisons A, B, and C were slightly negative (µA=0.959, µC=0.778, µD=0.608),
but none exceeded more than 1.7-fold down-regulation. Comparison A had an average foldchange in expression of 1.43.

48

Table 3) Up-regulated miRNAs in comparisons A through D with expression fold changes greater than two standard deviations above the mean
fold change; µ is the geometric mean of all amplified miRNAs in the comparison; σ is one geometric standard deviation
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Table 4) Down-regulated miRNAs in comparisons A through D with negative expression fold changes greater than two standard deviations
below the mean fold change; µ is the geometric mean of all amplified miRNAs in the comparison; σ is one geometric standard deviation
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Significantly deregulated miRNAs were then analyzed in a manner illustrated by the
Venn diagrams in Figure 3. All miRNAs that showed three-fold deregulation in any of the
comparison groups of Table 1 were included in the Venn diagrams for either up- or downregulated miRNAs, and a small number of miRNAs were included in both diagrams. The
numbers in the figure represent the number of miRNAs in a specific section of the Venn
diagram. In all, 60 miRNAs were up-regulated in Comparison B (three weeks CDX vs. three
weeks CS-FBS) and at least one other comparison group. 17 miRNAs were up-regulated in CDX
treated cells compared to CS-FBS-only treated cells at both one week and three weeks
timepoints, Comparisons A and B. Two miRNAs, miR-RC-751 and miR-RC-308, also showed
significant up-regulation between the one week and three weeks CDX timepoints, Comparison
C. Several miRNAs included in the Venn diagram analysis had also been deemed significant due
to z-scores greater than 2.0 or less than -2.0, and these miRNAs are identified in red in Figure 3
and Figure 4.
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Figure 3) Venn diagram cross-comparison analysis of up-regulated miRNAs for comparisons A through D;
miRNAs in red have fold changes of two standard deviations or greater above the mean fold change in at
least one comparison
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The down-regulated miRNAs in Figure 4 consists of 29 miRNAs that exhibited three-fold
or greater down-regulation in Comparison B and either or both Comparison C and/or
Comparison D. Only one miRNA, miR-RC-593, was significantly down-regulated at both the
one week and three weeks CDX timepoints, Comparisons A and B. MiR-RC-593 was also downregulated in Comparison D, CDX treatment compared to androgen insensitive cells.
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Figure 4) Venn diagram cross-comparison analysis of down-regulated miRNAs for comparisons A through
D; miRNAs in red have fold changes of two standard deviations or greater below the mean fold change in at
least one comparison
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The primary objective of this study was to identify a group of miRNAs which show
significantly altered expression during CDX treatment to be used for developing clinical
screening procedures as well as for further investigation of cancer progression mechanisms.
These candidate miRNAs were identified based on the previously described comparison methods
and are presented in Table 5 as an array of primary candidate miRNAs. Up-regulated primary
candidate miRNAs were chosen from the top-ranked miRNAs that had expression values greater
than two standard deviations above the mean expression change in CDX treated cells at three
weeks, compared to CS-FBS treated cells or to zero hour LNCaP-104R1 cells, Comparisons B
and D. Since none of the very highly ranked up-regulated miRNAs were up-regulated in multiple
comparisons, none of the miRNAs appearing in Figure 3 were included in the array of primary
candidates. Candidate miRNAs for the down-regulated group were chosen on the condition that
they showed at least two standard deviations of down-regulation in any comparison and also at
least three-fold down-regulation in CDX treated cells at three weeks. Again, the top ranked
miRNAs were given preference. We chose 28 primary candidate miRNAs, with 14 exhibiting
overall up-regulation and 14 exhibiting overall down-regulation. The number of candidate
miRNAs included in the primary candidates array was intentionally kept relatively low to
facilitate results in the next stage of data analysis, target prediction. The order of miRNAs
presented in Table 5 cannot objectively be considered the order of significance.

55

Table 5) Primary candidate array of most significantly deregulated candidate miRNAs
Primary Candidate MicroRNAs
Up-regulated
Down-regulated
miR-RC-640
miR-RC-639
miR-RC-576
miR-RC-175
miR-RC-623
miR-RC-375
miR-RC-272
miR-RC-632
miR-RC-622
miR-RC-141
miR-RC-562
miR-RC-517
miR-RC-309
miR-RC-197

miR-RC-301
miR-RC-649
miR-RC-291
miR-RC-442
miR-RC-759
miR-RC-599
miR-RC-220
miR-RC-878
miR-RC-407
miR-RC-603
miR-RC-528
miR-RC-329
miR-RC-490
miR-RC-247
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To serve as a more complete collection of candidate miRNAs for future screening
purposes, a second array of miRNAs was constructed, referred to as the secondary array of
candidate miRNAs and presented in Table 6. This array encompassed all the miRNAs included
in the primary array, plus other significantly deregulated candidates. Any miRNA that had zscores greater 3.0 or less than -3.0 and any miRNA that was at least three-fold deregulated in
Comparison B and one other comparison (all miRNAs listed in Figure 3 and Figure 4) were
included as elements in the secondary array of candidate miRNAs. The secondary array consists
of 102 upregulated miRNAs and 85 down-regulated miRNAs.
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Table 6) Secondary candidate array of significantly deregulated candidate miRNAs
Secondary Candidate MicroRNAs
Up-regulated
Down-regulated
miR-RC-707

miR-RC-376

miR-RC-104

miR-RC-881

miR-RC-822

miR-RC-750

miR-RC-258

miR-RC-682

miR-RC-761

miR-RC-796

miR-RC-556

miR-RC-140

miR-RC-702

miR-RC-303

miR-RC-825

miR-RC-364

miR-RC-244

miR-RC-588

miR-RC-735

miR-RC-698

miR-RC-554

miR-RC-680

miR-RC-557

miR-RC-874

miR-RC-523

miR-RC-326

miR-RC-671

miR-RC-589

miR-RC-719

miR-RC-414

miR-RC-751

miR-RC-57

miR-RC-558

miR-RC-199

miR-RC-326

miR-RC-751

miR-RC-564

miR-RC-672

miR-RC-857

miR-RC-247

miR-RC-538

miR-RC-329

miR-RC-308

miR-RC-693

miR-RC-39

miR-RC-630

miR-RC-593

miR-RC-771

miR-RC-22

miR-RC-556

miR-RC-843

miR-RC-674

miR-RC-26

miR-RC-590

miR-RC-301

miR-RC-527

miR-RC-857

miR-RC-535

miR-RC-487

miR-RC-22

miR-RC-747

miR-RC-649

miR-RC-575

miR-RC-726

miR-RC-46

miR-RC-638

miR-RC-587

miR-RC-710

miR-RC-291

miR-RC-559

miR-RC-794

miR-RC-816

miR-RC-598

miR-RC-716

miR-RC-301

miR-RC-442

miR-RC-653

miR-RC-591

miR-RC-101

miR-RC-412

miR-RC-866

miR-RC-649

miR-RC-759

miR-RC-545

miR-RC-9

miR-RC-283

miR-RC-640

miR-RC-656

miR-RC-291

miR-RC-599

miR-RC-344

miR-RC-395

miR-RC-345

miR-RC-639

miR-RC-238

miR-RC-442

miR-RC-628

miR-RC-256

miR-RC-330

miR-RC-620

miR-RC-576

miR-RC-28

miR-RC-759

miR-RC-220

miR-RC-75

miR-RC-14

miR-RC-157

miR-RC-175

miR-RC-678

miR-RC-599

miR-RC-590

miR-RC-448

miR-RC-605

miR-RC-13

miR-RC-623

miR-RC-392

miR-RC-628

miR-RC-700

miR-RC-78

miR-RC-380

miR-RC-238

miR-RC-375

miR-RC-283

miR-RC-220

miR-RC-878

miR-RC-534

miR-RC-678

miR-RC-312

miR-RC-272

miR-RC-517

miR-RC-700

miR-RC-529

miR-RC-450

miR-RC-7

miR-RC-393

miR-RC-632

miR-RC-309

miR-RC-878

miR-RC-343

miR-RC-327

miR-RC-307

miR-RC-28

miR-RC-622

miR-RC-197

miR-RC-407

miR-RC-300

miR-RC-178

miR-RC-449

miR-RC-286

miR-RC-141

miR-RC-761

miR-RC-603

miR-RC-247

miR-RC-227

miR-RC-402

miR-RC-392

miR-RC-562

miR-RC-843

miR-RC-528

miR-RC-528

miR-RC-328

miR-RC-257

miR-RC-461

miR-RC-477

miR-RC-799

miR-RC-530

miR-RC-407

miR-RC-422

miR-RC-884

miR-RC-797

miR-RC-66

miR-RC-340

miR-RC-12

miR-RC-375

miR-RC-346

miR-RC-717

miR-RC-660

miR-RC-738

miR-RC-452

miR-RC-304

miR-RC-868

miR-RC-537

miR-RC-465

miR-RC-63
miR-RC-329

miR-RC-603

miR-RC-288
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The top miRDB (miRNA DataBase, http://mirdb.org) target prediction results for the
miRNAs of the up-regulated and down-regulated lists of the primary array of candidates are
presented in Table 7 and Table 8, respectively. The miRDB score is the cumulative target score
for a single miRNA and a single mRNA transcript assigned by the internet-based prediction
software miRDataBase, with 100 being the highest score possible. The TargetScan Human
column is checked if the miRNA-target prediction is validated by internet-based prediction
database TargetScan Human. Refer to Materials and Methods for a description of how targets
were chosen for inclusion in Figure 7 and Figure 8. Several genes are predicted targets of more
than three up-regulated primary candidate miRNAs, including SH3TC2, CLASP2, AAK1,
GTF2H1, and NARG1. The genes ZEB1 and ZEB2 are targeted by miR-RC-517 with a miRDB
score of 100, the highest score possible. Also of note, the genes ZEB1, ZEB2, SLC7A11, TET2,
TMEM170B, UBE2B, ALS2CR2, CYP20A1, ERRFI1, SH3TC2, SLC35B4, TNRC6B,
ZKSCAN1, and ZNF826 are targeted by at least one up-regulated miRNA with a score of 99.0 or
greater.
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Table 7) Predicted target genes of up-regulated miRNAs; TS column shows validation of target match with the TargetScan Human database
(miR-1914 is not included in the TargetScan Human database)
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Down-regulated miRNAs of the primary candidate array have 11 very significant
predicted targets, but only ZNF776 is targeted by more than two miRNAs and receives at least
one score of 80.0 or above. The genes LATS2 and ZKSCAN1 are both predicted targets of miRRC-407 and have miRDB scores of 99.0. The genes ZKSCAN1 and SH3TC2 are strongly
predicted targets of miRNAs belonging to both the up-regulated and down-regulated lists of the
primary candidates array.
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Table 8) Predicted target genes of down-regulated miRNAs; TS column shows validation of target match with
the TargetScan Human database (miR-1972 is not included in the TargetScan Human database)
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DISCUSSION
In this study we sought to investigate the deregulation of miRNAs in human prostate
cancer treated with the anti-androgen drug Casodex and to shed light on the possible functional
roles of deregulated miRNAs in the progression of prostate cancer cells toward anti-androgen
resistance. Extensive analysis of expression for almost all known human miRNA sequences was
carried out, and an array of deregulated miRNAs was identified, as were several putative
regulatory target genes. The data suggest that some form of miRNA regulation is at play in the
progression of androgen sensitive LNCaP cells to a castration resistant phenotype. Quantitative
PCR is the most sensitive method of measuring gene expression available, so large changes
measured in the expression of miRNA genes can be taken as a reflection of cellular regulation
involving cancer progression processes and the effects of CDX treatment. The comparisons of
expression values that were carried out revealed that several miRNAs were up- and downregulated. Interestingly, the initial ΔΔCt method analysis and cluster analysis revealed that
approximately 75% of the miRNAs screened shown some pattern down-regulation when prostate
cancer cells were subjected to stimuli of androgen independence. This overall decrease in
miRNA production might be a signal of general deregulation of cellular processes, contributing
to more aggressive cancer phenotypes.
The miRNAs miR-RC-301, miR-RC-442, miR-RC-291, and miR-RC-599 had the most
widespread down-regulation of the miRNAs screened. They were significantly down-regulated
in androgen sensitive cells treated with CDX for three weeks compared to androgen sensitive
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cells treated only with CS-FBS, and they were also found to be down-regulated in androgen
sensitive cells treated with CDX for three weeks compared to androgen insensitive LNCaP104R1 cells. MiR-RC-599 showed significant decrease in expression between the one week and
three week timepoints of CDX treatment in androgen sensitive cells. These expression patterns
strongly indicate that these miRNAs have high potential for being implicated in the regulation of
progression to the androgen independent phenotype. There are known cancer roles for the
miRNAs corresponding to our sequences miR-RC-301 and miR-RC-442. Hsa-miR-199a-5p has
been shown to be down-regulated in the progression process of oral cancers in hamster models
(Yu et al., 2009). This same down-regulated expression pattern was seen in our cancer
progression model. Investigation into therapeutic targets for leukemia has revealed that miR-337
down-regulation is associated with overexpression of the tyrosine kinase Lyn, possibly
contributing to the rise of malignant phenotypes in certain types of leukemia (Hussein et al.,
2009). Again, this same expression pattern was seen in our model, suggesting that the activity of
Lyn kinase could contribute to CDX-resistance.
Another miRNA found to be consistently down-regulated was miR-RC-220. It was
recently shown that repression of malignant characteristics and some cell cycle arrest at the G1/S
transition are seen when knocked-down expression of this miRNA is restored in hepatocellular
carcinoma cells. The same study presented evidence that the miRNA targets the mRNA of
CCND2 (Cyclin D2) (Wang et al., 2010). We did not strongly predict CCND2 as a target of
miRNA regulation most likely due to the array-based approach taken to target prediction, with
preference given to targets that received multiple hits. The down-regulation of miR-RC-220 in
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cells progressing to CDX-resistance may lead to decreased inhibition of cyclin D2 function and
increased survival due to accelerated G1/S transition.
We also found that miR-RC-590 was down-regulated during progression to CDXresistance. This result has been corroborated by a study of miRNA expression in clear renal cell
carcinoma tissue samples, where it was found that miR-514 (corresponding to our miR-RC-590
sequence) is very highly down-regulated compared to matched non-malignant samples. It is,
however, unclear whether low miR-514 levels are part of a cancer affecter mechanism or just the
result of an altered regulatory mechanism, as no correlation between miR-514 expression and
tumor stage or survival were found (Jung et al., 2009). It was also determined in our study that
the miRNA miR-RC-247 (corresponding to hsa-miR-184) is significantly down-regulated during
CDX-treatment of androgen sensitive cells. There is evidence that miR-184 has tumor suppressor
functions through indirect inhibition of the Akt pathway. It was found that miR-184 can bind to
and repress the function of another miRNA, miR-205, which itself represses the enzyme SHIP2
(thought to inhibit Akt signaling) (Yu et al., 2008).
The miRNAs in the up-regulated list of primary candidates demonstrated less consistency
in expression across our four comparison analyses, but still resulted in some important findings.
Firstly, the two most highly up-regulated miRNAs in androgen sensitive cells treated with CDX
for three weeks compared to androgen sensitive cells treated only with CSFBS were miR-RC640 and miR-RC-639, with 126.045 and 64.772 fold up-regulation respectively. Interestingly,
these miRNA sequences arise from the same primary miRNA hairpin, being cleaved from

65

opposite arms of the hairpin by dicer. Increased expression of the primary hairpin transcript and
subsequent retention of both possible strands suggests that these miRNAs are involved in CDXinduced drug resistance. Another miRNA found to be significantly up-regulated in our study was
miR-RC-197. This finding is contrary to the pattern found in one study that reported downregulation of miR-146a (corresponding to miR-RC-197) in androgen independent prostate
cancer, leading to increased expression of its regulatory target ROCK1 (Lin et al., 2008).
However, it may be the case that miR-146a down-regulation is an effect of depleted androgen
levels and that the effects of anti-androgen binding include increased miR-146a expression.
Two members of the miR-200 family exhibited significant differential expression and
were included in the primary candidate array of up-regulated miRNAs, miR-RC-517 and miRRC-309. It has been shown by several studies that up-regulation of these miRNAs are important
for migration of certain cancers. Mesenchymal (metastatic) ovarian cancer cells overexpress the
miR-200 family miRNA miR-429 compared to non-metastatic ovarian cancer cells. Additionally,
the transcription factors ZEB1 and ZEB2 are known targets of miR-429. ZEB1 and ZEB2 levels
are decreased in ovarian cancer cells when miR-429 is overexpressed (Chen et al., 2011),
corroborating the miRNA expression and target prediction results of our study. MiR-200a has
also been implicated in migration through targeting of ZEB2 in nasopharyngeal carcinoma cells
(Xia et al., 2010).
The genes LATS2, ZKSCAN1, LPAR4, and VPS53 were the most highly predicted to be
regulatory targets of down-regulated miRNAs, suggesting an increase in expression of the genes
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in question. LATS2 is a known tumor suppressor gene that has lowered expression in a diverse
array of cancers, including prostate cancer. In a genomic study of malignant mesothelioma cell
lines, the majority of the studied lines showed deletion or mutation of the LATS2 gene. IT was
also found that LATS2 inhibits the YAP oncogene by phosphorylation (Murakami et al., 2011).
Another study showed that in breast and prostate tissues decreased expression of LATS2 is
possibly due to a defective mutation in the transcription factor FOXP3 (Li et al., 2011). Given
the very high score assigned to the miR-RC-407/LATS2 interaction by miRDB (99.0), it is
extremely probable that the target prediction is accurate. However, more complex regulatory
pathways than can be elucidated by this screening study alone may be at play. Two gene targets
were predicted for both up- and down-regulated miRNAs of the primary candidate array.
ZKSCAN1 is a strongly predicted target of miR-RC-623 and miR-RC-407. SH3TC2 is a
strongly predicted target of multiple up- and down-regulated miRNAs. It is expected that in the
case of multiple regulatory miRNAs specific for the same mRNA transcript, the effect of the upregulated miRNA would be phenotypically apparent, i.e. decreased expression of the target gene.
It is important that the miRNA screening be replicated for the candidate miRNAs chosen
from this preliminary investigation in matched samples of patient tumors before and following
the acquisition of an androgen independent phenotype. Additionally, the genes predicted as
targets in this study should be the focus of further investigations to verify both that expression of
these genes are altered upon treatment with CDX and that these genes are indeed targeted by the
deregulated miRNAs as predicted.
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In conclusion, the genome-wide miRNA expression screening resulted in an array of both
up-regulated and down-regulated candidate miRNAs that have altered expression in androgen
sensitive LNCaP cells as a result of treatment with CDX, separate from the effects of androgen
depletion alone. 28 miRNAs exhibiting differential expression in the process of acquiring drug
resistance were compiled into an array of primary miRNA candidates for diagnostic and
therapeutic use. These miRNAs could have clinical implications as part of a screening test to
more accurately identify the level of progression to drug resistance or to predict the effectiveness
of anti-androgen therapy in a patient. Uses of miRNA markers that would lead to more selective
use of anti-androgen therapy would certainly be worthwhile if it would make it possible to avoid
the certain decline in quality of life for patients undergoing cancer therapy. This study forms the
groundwork for further studies to validate the expression profiles of the identified miRNAs and
to characterize the putative miRNA-target interactions.
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